JP2022513597A5 - - Google Patents

Info

Publication number
JP2022513597A5
JP2022513597A5 JP2021525191A JP2021525191A JP2022513597A5 JP 2022513597 A5 JP2022513597 A5 JP 2022513597A5 JP 2021525191 A JP2021525191 A JP 2021525191A JP 2021525191 A JP2021525191 A JP 2021525191A JP 2022513597 A5 JP2022513597 A5 JP 2022513597A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antisense oligonucleotide
administered
dose
nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525191A
Other languages
English (en)
Japanese (ja)
Other versions
JP7612575B2 (ja
JP2022513597A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065936 external-priority patent/WO2020123783A1/en
Publication of JP2022513597A publication Critical patent/JP2022513597A/ja
Publication of JP2022513597A5 publication Critical patent/JP2022513597A5/ja
Priority to JP2024213950A priority Critical patent/JP2025023319A/ja
Application granted granted Critical
Publication of JP7612575B2 publication Critical patent/JP7612575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525191A 2018-12-14 2019-12-12 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法 Active JP7612575B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213950A JP2025023319A (ja) 2018-12-14 2024-12-06 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862779916P 2018-12-14 2018-12-14
US62/779,916 2018-12-14
US201962807603P 2019-02-19 2019-02-19
US62/807,603 2019-02-19
US201962840879P 2019-04-30 2019-04-30
US62/840,879 2019-04-30
PCT/US2019/065936 WO2020123783A1 (en) 2018-12-14 2019-12-12 Compositions and methods for treating and preventing amyotrophic lateral sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213950A Division JP2025023319A (ja) 2018-12-14 2024-12-06 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022513597A JP2022513597A (ja) 2022-02-09
JP2022513597A5 true JP2022513597A5 (https=) 2022-10-27
JP7612575B2 JP7612575B2 (ja) 2025-01-14

Family

ID=69160351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525191A Active JP7612575B2 (ja) 2018-12-14 2019-12-12 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法
JP2024213950A Pending JP2025023319A (ja) 2018-12-14 2024-12-06 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213950A Pending JP2025023319A (ja) 2018-12-14 2024-12-06 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法

Country Status (20)

Country Link
US (1) US20220073930A1 (https=)
EP (1) EP3894557A1 (https=)
JP (2) JP7612575B2 (https=)
KR (2) KR20250090384A (https=)
CN (3) CN118987017A (https=)
AU (1) AU2019396522B2 (https=)
BR (1) BR112021011334A2 (https=)
CA (1) CA3115549A1 (https=)
CL (1) CL2021001136A1 (https=)
CO (1) CO2021008187A2 (https=)
CR (1) CR20210384A (https=)
IL (1) IL283833A (https=)
JO (1) JOP20210143A1 (https=)
MX (1) MX2021005086A (https=)
MY (1) MY209775A (https=)
PH (1) PH12021551365A1 (https=)
SG (1) SG11202103415WA (https=)
TW (1) TWI906204B (https=)
UY (1) UY38506A (https=)
WO (1) WO2020123783A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
CN119679944A (zh) 2018-01-25 2025-03-25 渤健马萨诸塞州股份有限公司 治疗脊髓性肌萎缩症的方法
US12429487B2 (en) 2018-12-06 2025-09-30 Biogen Ma Inc. Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis
BR112023019877A2 (pt) * 2021-03-31 2023-11-07 Biogen Ma Inc Tratamento de esclerose lateral amiotrófica
WO2025045130A1 (zh) * 2023-08-29 2025-03-06 石药集团中奇制药技术（石家庄）有限公司 一种抑制sod1基因表达的dsrna分子及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
WO2013134403A1 (en) * 2012-03-06 2013-09-12 The Washington University Method of treating neurodegenerative diseases with microrna regulators
EP3119888B1 (en) * 2014-03-19 2021-07-28 Ionis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
HUE050704T2 (hu) * 2014-04-01 2020-12-28 Biogen Ma Inc Összetételek a SOD-1 expressziójának modulálására
WO2016077687A1 (en) * 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020518258A (ja) * 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
WO2018218219A1 (en) * 2017-05-26 2018-11-29 University Of Miami Determining onset of amyotrophic lateral sclerosis

Similar Documents

Publication Publication Date Title
JP2022513597A5 (https=)
JP7198298B2 (ja) Ｓｏｄ－１発現を調節するための組成物
RU2566724C9 (ru) Композиции и способы модуляции smn2 сплайсинга у субъекта
JP7438103B2 (ja) アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物
EP2812342B1 (en) Modulation of rna by repeat targeting
US20250270555A1 (en) Organic compositions to treat beta-catenin-related diseases
JP2021104035A (ja) アタキシン２の発現を調節するための組成物
HK1246648A1 (en) Compositions and methods for modulation of smn2 splicing in a subject
CN104994884B (zh) 对脂蛋白脂肪酶缺乏(lpld)群体中的载脂蛋白c-iii(apociii)表达的调节
CN103547271A (zh) 载脂蛋白ciii（apociii）表达的调节
JP7612575B2 (ja) 筋萎縮性側索硬化症を治療及び予防するための組成物及び方法
TW202016305A (zh) Ａｐｏｌ１表現之調節劑
JP2022527105A (ja) Ｕｂｅ３ａ－ａｔｓを調節するための化合物及び方法
CN119365598A (zh) 用于治疗单基因神经发育障碍的组合物和方法
CN114786683B (zh) 一种siRNA、药物组合物以及使用其治疗糖尿病的方法
TW202227101A (zh) 用於調節血管收縮素原表現之化合物及方法
RU2021112868A (ru) Составы и способы лечения и предотвращения бокового амиотрофического склероза
RU2024121642A (ru) Составы и способы лечения и предотвращения бокового амиотрофического склероза
CN121358862A (zh) 用于治疗肾脏疾病的组合物和方法
WO2019161294A1 (en) Targeting lipid metabolism and free fatty acid (ffa) oxidation to treat diseases mediated by resident memory t cells (trm)
TW202540430A (zh) 使用靶向血管生成素樣3（angptl3）的rnai藥劑治療血脂異常的方法
HK40120557A (en) Compounds and methods for modulating angiotensinogen expression
HK40000192A (en) Compositions and methods for modulation of smn2 splicing in a subject
HK40000192B (en) Compositions and methods for modulation of smn2 splicing in a subject
HK40025555A (en) Compositions and methods for modulation of smn2 splicing in a subject